Vaccine for Infectious Diseases 

Canthevac specializes in the development of preventive vaccines for emerging infectious diseases. We have a promising candidate called IBIS, which aims to provide cross-protection against different strains of SARS-CoV-like viruses, including those responsible for SARS in 2003 and the recent COVID-19 pandemic. Additionally, our team is actively working on a vaccine for respiratory syncytial virus (RSV), a virus that can cause severe illness, especially among infants and older adults. We are exploring the potential of creating vaccines for other infectious diseases, including MERS, dengue virus, influenza, and Zika virus. 
 

Cancer Therapeutics

As part of our ongoing efforts, Canthevac is actively exploring the application of our vaccine platform in the field of cancer therapeutics. Our primary objective is to develop groundbreaking treatments that can effectively stimulate a robust immune response against cancer cells. In the initial stage, we are focusing on non-small cell lung cancer, working towards innovative therapeutic solutions. Moreover, we are investigating the potential of developing effective therapeutics for other types of cancer, including pancreatic cancer and colorectal cancer.